[go: up one dir, main page]

GT200900112A - Tratamiento de los trastornos generalizados del desarrollo - Google Patents

Tratamiento de los trastornos generalizados del desarrollo

Info

Publication number
GT200900112A
GT200900112A GT200900112A GT200900112A GT200900112A GT 200900112 A GT200900112 A GT 200900112A GT 200900112 A GT200900112 A GT 200900112A GT 200900112 A GT200900112 A GT 200900112A GT 200900112 A GT200900112 A GT 200900112A
Authority
GT
Guatemala
Prior art keywords
treatment
development
generalized
disorders
generalized disorders
Prior art date
Application number
GT200900112A
Other languages
English (en)
Inventor
Magali Haas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900112A publication Critical patent/GT200900112A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION ESTA DIRIGIDA AL USO DE ALGUNOS COMPUESTOS DE CARBAMATO PARA EL TRATAMIENTO DE PACIENTES CON TRASTORNOS GENERALIZADOS DEL DESARROLLO (PDD'S) QUE SON UNA CATEGORIA DE TRASTORNOS NEUROLOGICOS CARACTERIZADOS POR DETERIORO SEVERO Y GENERALIZADO TALES COMO EL AUTISMO.
GT200900112A 2006-10-31 2009-04-30 Tratamiento de los trastornos generalizados del desarrollo GT200900112A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86359506P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
GT200900112A true GT200900112A (es) 2010-05-18

Family

ID=39145417

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900112A GT200900112A (es) 2006-10-31 2009-04-30 Tratamiento de los trastornos generalizados del desarrollo

Country Status (17)

Country Link
US (1) US20080103199A1 (es)
EP (1) EP2089011A1 (es)
JP (1) JP2010508354A (es)
KR (1) KR20090080105A (es)
CN (1) CN101568333A (es)
AU (1) AU2007313911A1 (es)
BR (1) BRPI0718323A2 (es)
CA (1) CA2667909A1 (es)
CO (1) CO6180427A2 (es)
EA (1) EA200970435A1 (es)
GT (1) GT200900112A (es)
IL (1) IL198488A0 (es)
MX (1) MX2009004798A (es)
NI (1) NI200900074A (es)
NO (1) NO20092019L (es)
WO (1) WO2008054984A1 (es)
ZA (1) ZA200903772B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
WO2010020585A1 (en) * 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
WO2012018387A2 (en) 2010-08-02 2012-02-09 Population Diagnotics, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
DK2766483T3 (da) 2011-10-10 2022-04-19 Hospital For Sick Children Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
DK2773779T3 (da) 2011-11-04 2020-11-23 Population Bio Inc Fremgangsmåder og sammensætninger til diagnosticering, prognose og forebyggelse af neurologiske tilstande
WO2013120018A1 (en) * 2012-02-09 2013-08-15 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
HK1211239A1 (en) * 2012-08-06 2016-05-20 S1 Biopharma, Inc. Treatment regimens
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
CA2922005A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
KR20160004260A (ko) * 2013-03-12 2016-01-12 (주)바이오팜솔루션즈 페닐카바메이트 화합물 및 이를 포함하는 신경보호용 조성물
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
MY199104A (en) * 2016-12-14 2023-10-13 Sk Biopharmaceuticals Co Ltd Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
FI4177356T3 (fi) 2018-08-08 2024-08-07 Pml Screening Llc Menetelmiä virustaudin kehittymisriskin arviointiin geenitestillä
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4276837B2 (ja) * 2001-02-27 2009-06-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 双極性障害の予防もしくは治療における使用のためのカルバメート化合物
RU2294739C2 (ru) * 2001-02-27 2007-03-10 Орто-Макнейл Фармасьютикал, Инк. Производные карбамата для применения для предупреждения или лечения расстройств движений
JP4276841B2 (ja) * 2001-02-27 2009-06-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 精神病性障害の予防もしくは治療における使用のためのカルバメート化合物
PT1383489E (pt) * 2001-02-27 2007-06-21 Ortho Mcneil Pharm Inc Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos
CA2580640A1 (en) * 2004-09-16 2006-03-30 Janssen Pharmaceutica N.V. Methods of treating epileptogensis and epilepsy

Also Published As

Publication number Publication date
NO20092019L (no) 2009-06-23
MX2009004798A (es) 2009-08-12
CN101568333A (zh) 2009-10-28
CA2667909A1 (en) 2008-05-08
WO2008054984A1 (en) 2008-05-08
KR20090080105A (ko) 2009-07-23
NI200900074A (es) 2010-02-01
BRPI0718323A2 (pt) 2013-11-26
ZA200903772B (en) 2010-08-25
IL198488A0 (en) 2010-02-17
EP2089011A1 (en) 2009-08-19
EA200970435A1 (ru) 2009-10-30
JP2010508354A (ja) 2010-03-18
AU2007313911A1 (en) 2008-05-08
CO6180427A2 (es) 2010-07-19
US20080103199A1 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
GT200900112A (es) Tratamiento de los trastornos generalizados del desarrollo
ECSP077275A (es) Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ECSP12011968A (es) Nuevos compuestos tricíclicos
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2012000151A (es) Nuevos compuestos triciclicos
ECSP066730A (es) Compuestos y procedimientos para uso
CR9485A (es) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
GT200700103A (es) Compuestos biciclocarboxiamida sustituidos
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
ECSP12007795A (es) 1h-quinazolin-2,4-dionas y su uso como ligandos del receptor de ampa
CO6382118A2 (es) Nuevas octahidrociclopenta(c)ciprol-4aminas sustituidas como bloqueantes de los canales de calcio
BRPI0518169A (pt) tiazolil-dihidro-indazóis
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
PA8603001A1 (es) Compuestos utiles para el tratamiento de enfermedades
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
AR057239A1 (es) Inmunoglobulinas
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos